Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with relapsed/metastatic cancers. By drawing on lessons learned durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, K.J., Vile, R.G., Melcher, A., Chester, J., Pandha, H.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915505/
https://www.ncbi.nlm.nih.gov/pubmed/20223697
http://dx.doi.org/10.1016/j.cytogfr.2010.02.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915505/
https://www.ncbi.nlm.nih.gov/pubmed/20223697
http://dx.doi.org/10.1016/j.cytogfr.2010.02.006

Ejemplares similares